-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Beam Therapeutics, Raises Price Target to $79

Benzinga·10/29/2026 21:55:17
Listen to the news
Canaccord Genuity analyst Whitney Ijem maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and raises the price target from $78 to $79.